Anna M. Upton

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “The Tuberculosis Drug Accelerator at year 10: what have we learned?”.

The Tuberculosis Drug Accelerator at year 10: what have we learned?

Nature Medicine(2021)10.1038/s41591-021-01442-2

N/A

0DataRank · unranked

62 citations

David Barros-Aguirre, Clifton E. Barry, Robert H. Bates, Steven J. Berthel, Helena I. Boshoff +32 more

Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs

Nature Communications(2022)10.1038/s41467-022-33736-5

N/A

0DataRank · unranked

34 citations

Susan H. Davis, Sebastian Damerow, Curtis A. Engelhart, Michael Mathieson, Beatriz Baragaña +40 more

The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection

Microbiology Spectrum(2022)10.1128/spectrum.02451-21

N/A

0DataRank · unranked

15 citations

Dustin Dikeman, Roger V. Ortines, Yu Wang, Christine Youn, Mohammed Mumtaz +11 more

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.02.04.479214

N/A

0DataRank · unranked

11 citations

Maria Santos Martínez, Olalla Sanz, Beatriz Urones, Jorge Esquivias, Heena Soni +25 more

Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents

Cell(2023)10.1016/j.cell.2023.01.043

N/A

0DataRank · unranked

24 citations

Christine Lair, Christine Roubert, Kwame Amaning, María Belén Pascual Barrio, Yannick Benedetti +26 more